葡萄膜炎的缓释治疗给药研究进展  

Research progress of sustained-release drug delivery system for uveitis

作　　者：朱婷 徐达华 王晓琳 陈梅 Zhu Ting;Xu Dahua;Wang Xiaolin;Chen Mei(Aier School of Ophthalmology,Central South University,Changsha 410009,Hunan Province,China;Department of Ophthalmology,Affiliated Hospital of Hubei University of Medicine,Shiyan 442000,Hubei Province,China;Chongqing Aier Eye Hospital,Chongqing 400020,China)

机构地区：[1]中南大学爱尔眼科学院,湖南省长沙市410009 [2]湖北医药学院附属医院眼科,湖北省十堰市442000 [3]重庆爱尔眼科医院,重庆市400020

出　　处：《国际眼科杂志》2024年第2期236-240,共5页International Eye Science

基　　金：湖南省自然科学基金面上项目(No.2023JJ30001);爱尔眼科医院集团科研项目(No.AC2001D1)。

摘　　要：葡萄膜炎病因繁多,发生机制复杂,感染、自身免疫及各种理化和机械损伤因素等均可引起,治疗较为棘手,未得到及时有效治疗常可导致失明。随着人们对葡萄膜炎及其相关机制认识的加深,各种新型的葡萄膜炎缓释治疗给药系统被研究,但是,由于眼部各种解剖学和生理学屏障的存在,使得葡萄膜炎的缓释治疗存在多重阻碍。本文综述了该领域近年来的主要研究成果,讨论了各新型缓释给药系统的创新点和局限性,以期能为未来葡萄膜炎的缓释给药治疗提供新思路。这些新型缓释给药系统有助于在未来彻底改变葡萄膜炎治疗副作用大、依从性差的传统治疗模式,带来更长时间的靶向缓释和更少的毒性反应。Uveitis,a complex ocular disorder with numerous etiologies,can result from infection,autoimmune,and various physicochemical and mechanical injury factors.The treatment of this disease is difficult,and failure to receive timely and effective treatment can often lead to blindness.With the deepening of people’s understanding of uveitis and its related mechanisms,various new sustained-release drug delivery systems for uveitis have been studied.However,due to the existence of various anatomical and physiological barriers in the eye,there are multiple obstacles to the sustained release treatment of uveitis.In this paper,the main research results in this field in recent years are reviewed,and the innovations and limitations of various new sustained-release drug delivery systems are discussed in order to provide new ideas for the sustained-release drug delivery treatment of uveitis in the future.These new sustained-release drug delivery systems will help to completely change the traditional treatment mode of uveitis with side effects and poor compliance in the future,bringing longer targeted sustained release and less toxic reactions.

关 键 词：葡萄膜炎 缓释制剂 药物递送系统 

分 类 号：R773[医药卫生—眼科]